Clinical Trials Logo

Brain Neoplasms clinical trials

View clinical trials related to Brain Neoplasms.

Filter by:

NCT ID: NCT02006407 Active, not recruiting - Clinical trials for Brain Tumor, Primary

A Pilot Study to Evaluate Neurocognitive Injury and Longitudinal Changes in White Matter During Radiation Therapy in Children With Primary Brain Tumors

Start date: June 2013
Phase: N/A
Study type: Interventional

This is a pilot study to assess the changes in white matter, in the brain, in response to radiation therapy and correlate these changes with later declines in cognitive function.

NCT ID: NCT01892397 Active, not recruiting - Brain Cancer Clinical Trials

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

Start date: June 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to find out what effects, good or bad, the Optune device has on the patient and meningioma. This study is being done because currently there are no proven effective medical treatments for a progressive meningioma that has failed surgery and/or radiation. The study uses an experimental device called Optune. Optune is "experimental" because it has not been approved by the U.S. Food and Drug Administration (FDA) for this type of tumor, although it has been approved for a different type of brain tumor.

NCT ID: NCT01817751 Active, not recruiting - Glioblastoma Clinical Trials

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Start date: April 11, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to test the safety, tolerability, and effectiveness of the combination of three drugs, sorafenib (Nexavar®), valproic acid (Depakote®), and sildenafil (Viagra®), when used to treat high-grade glioma, a type of brain tumor.

NCT ID: NCT01755624 Active, not recruiting - Clinical trials for 1-5 Brain Metastases From Non-Small Cell Lung Cancer

Effect of TTFields (150kHz) in Non-small Cell Lung Cancer (NSCLC) Patients With 1-5 Brain Metastases Following Optimal Standard Local Treatment (COMET)

Start date: January 2013
Phase: Phase 2
Study type: Interventional

The study is a prospective, randomly controlled phase II trial, designed to test the efficacy, safety and neurocognitive outcomes of a medical device, the NovoTTF-100A, in the treatment of NSCLC patients with controlled systemic disease, following optimal standard local treatment for 1-5 brain metastases (BM). The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays.

NCT ID: NCT01644591 Active, not recruiting - Metastatic Melanoma Clinical Trials

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Start date: August 2, 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well stereotactic radiosurgery works in treating patients with melanoma that has spread to more than 3 places in the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

NCT ID: NCT01592968 Active, not recruiting - Clinical trials for Metastatic Malignant Neoplasm in the Brain

Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases

Start date: August 2, 2012
Phase: Phase 3
Study type: Interventional

This randomized phase III clinical trial compares stereotactic radiosurgery with whole brain radiation therapy to see how well they work in treating patients with non-melanoma cancer that has recently spread from the first location to the brain. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a specialized type of radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue. Whole brain radiation therapy delivers a lower dose of radiation to the entire brain over several treatments. It is not yet known whether stereotactic radiosurgery works better than whole brain radiation therapy in treating patients with non-melanoma brain metastases. Stereotactic radiosurgery may also cause fewer thinking and memory problems than whole brain radiation therapy.

NCT ID: NCT01538264 Active, not recruiting - Brain Tumors Clinical Trials

Blood Flow MRI for Monitoring Brain Tumors

Glioma
Start date: June 2006
Phase:
Study type: Observational

The investigators are studying the use of an advanced magnetic resonance imaging (MRI) technique for measuring blood flow into brain tumors. This technique does not use radioactive tracers, and it can provide high quality images that can be obtained in a standard MRI scanner.

NCT ID: NCT01535911 Active, not recruiting - Glioblastoma Clinical Trials

Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors

Ketones
Start date: April 1, 2012
Phase: N/A
Study type: Interventional

This study will look at the effects, good and/or bad, of treating primary brain cancers with diet therapy using an energy restricted ketogenic diet (ERKD) that uses food. An energy restricted ketogenic diet is a diet designed to keep blood sugars in the low range of normal while at the same time increasing the blood concentration of metabolic break down products called ketones. This diet is currently used to treat children with uncontrollable seizures. This diet is well tolerated by the children with minimal side effects reported after using the diet for years. - The main purpose of this study is to find out whether or not the energy restricted ketogenic diet will help patients with primary brain cancer by either decreasing the size of the cancer or by keeping the cancer from growing. - Another reason for doing this study is to learn about the side effects associated with the energy restricted ketogenic diet in patients with primary brain cancer.

NCT ID: NCT01503086 Active, not recruiting - Brain Neoplasm Clinical Trials

Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy

Start date: February 19, 2015
Phase: N/A
Study type: Interventional

This randomized clinical trial studies how well an adaptive computerized cognitive training program works compared to a non-adaptive computerized cognitive training program in treating younger patients with brain tumor who underwent radiation therapy. Providing a computer training program may improve the well-being and quality of life of patients with cognitive (physical and mental) function difficulties caused by radiation therapy to the brain.

NCT ID: NCT01494662 Active, not recruiting - Breast Cancer Clinical Trials

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Start date: February 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your thinking (or cognition) and how much neratinib reaches the central nervous system.